false 0001574094 0001574094 2024-08-16 2024-08-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 16, 2024 (August 12, 2024)

 

RenovoRx, Inc.
(Exact name of registrant as specified in its charter)

 

Delaware   001-40738   27-1448452

(State or other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

4546 El Camino Real, Suite B1

Los Altos, CA 94022

(650) 284-4433

(Address and telephone number, including area code, of registrant’s principal executive offices)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 4.01 Change in Registrant’s Certifying Accountant

 

As previously reported on May 3, 2024, on April 29, 2024, the Audit Committee (the “Audit Committee”) of the Board of Directors of RenovoRx, Inc. (the “Company”) received a letter from Baker Tilly US, LLP (“BT”), notifying the Committee that BT had decided to resign as the independent registered public accounting firm of the Company effective immediately following the filing of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024. Such Quarterly Report was filed, and BT’s resignation therefore became effective, on August 13, 2024.

 

On August 12, 2024, with the approval of the Audit Committee, the Company engaged Frank, Rimerman + Co. LLP (“Frank Rimerman”) as the Company’s independent public accounting firm to audit the Company’s financial statements for the fiscal year ending December 31, 2024 and to review the Company’s quarterly condensed financial statements for the Company’s fiscal quarter ending September 30, 2024.

 

For the Company’s two most recent fiscal years, and in the subsequent interim period through the date of this Current Report, neither the Company nor anyone on its behalf consulted with Frank Rimerman regarding: (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company that Frank Rimerman concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).

 

Frank Rimerman previously served as the independent registered public accounting firm of the Company for its fiscal year ended December 31, 2020.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  RenovoRx, Inc.
   
Date: August 16, 2024 By: /s/ Shaun Bagai
  Name: Shaun R. Bagai
  Title: Chief Executive Officer

 

 

v3.24.2.u1
Cover
Aug. 16, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 16, 2024
Entity File Number 001-40738
Entity Registrant Name RenovoRx, Inc.
Entity Central Index Key 0001574094
Entity Tax Identification Number 27-1448452
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4546 El Camino Real
Entity Address, Address Line Two Suite B1
Entity Address, City or Town Los Altos
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94022
City Area Code (650)
Local Phone Number 284-4433
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
RenovoRx (NASDAQ:RNXT)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more RenovoRx Charts.
RenovoRx (NASDAQ:RNXT)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more RenovoRx Charts.